New imaging analysis predicts brain tumor survival

Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute 

To cite this article: (2009) Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute, Cancer Biology & Therapy, 8:9, 753-752, DOI: 10.4161/cbt.8.9.8899 To link to this article: https://doi.org/10.4161/cbt.8.9.8899

New imaging analysis predicts brain tumor survival As early as one week after beginning treatment for brain tumors, a new imaging analysis method was able to predict which patients would live longer, researchers from the University of Michigan Comprehensive Cancer Center have found. The method uses a standard magnetic resonance imaging, or MRI, protocol to monitor changes over time in tumor blood volume within individual voxels of the image, rather than a composite view of average change within the tumor. This parametric response map allowed researchers to see specific areas in which tumor blood volume increased or decreased, that may have canceled each other out when looking at the changes as an average. Results of the study appeared in the advance online edition of Nature Medicine. “What we have potentially is a generalized analytical approach that we can use to quantify treatment intervention in patients,” says study author Brian Ross, Ph.D., professor of radiology and biological chemistry at the U-M Medical School and co-director of the Molecular Imaging Program at the U-M Comprehensive Cancer Center. The researchers looked at 44 people with high-grade glioma, a type of brain tumor, who were treated with chemotherapy and radiation. Each participant underwent MRIs before treatment, and one week and three weeks after starting treatment. The researchers then looked at the relative cerebral blood volume and the relative cerebral blood flow of the tumor to analyze voxel-wise changes among the serial scans. Looking at standard comparisons using averages, the scans indicated no change one week and three weeks into treatment. But, using the parametric response map approach, the researchers were able to show changes in the tumor’s blood volume and blood flow after one week that corresponded to the patient’s overall survival. “We’re seeing treatment response earlier into the treatment, and responses that couldn’t be detected at all looking at average changes. We could detect this after just one week, which is amazing for brain tumors,” says study author Craig Galbán, Ph.D., assistant professor of radiology at the U-M Medical School. High grade gliomas have a high mortality rate, with people surviving only an average of 12 months after diagnosis. Typically, patients receive 6–7 weeks of treatment, followed by a traditional MRI scan six weeks after completing therapy to determine if the tumor shrank. If the cancer did not respond to the treatment, a new approach may be tried. The researchers believe this approach might also be useful with other imaging techniques such as PET and CT scans.

https://www.tandfonline.com/doi/pdf/10.4161/cbt.8.9.8899

When general population speak of contemporary medicine, precision plays one of the most significant roles and human lives are directly dependent on it. Hereby, any researches pertaining to medicine are necessary to comply with the top standards. The challenge nowadays is that any results of researches can be published online and used as a reference without being thoroughly checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget clearly understood this issue and decided to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The main principle of this journal is based on Altmetric scores that are used as a quality measure. That assists both readers and authors to validate publications with Altmetric Article Reports that generate “real-time feedback containing data summary related to a particular publication.” Oncotarget website demonstrates a complete publications list with corresponding scores above 100 as well as reports mentioned previously. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it creates the necessary assistance to anyone, who has interest in oncology.
https://twitter.com/blagosklonny?lang=en
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was published back in 2018 by Oncotarget and completed by diversified experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are willing to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hereby, the paper about melanoma, was used for citations in various news articles 69 times. Moreover, it was referred to in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s study with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have seen a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do get helpful scientific facts. Oncotarget is glad to have the chance to share with online viewers this highly appreciated and high-quality information, that is trustworthy and reliable.
Blagosklonny